Advertisement

Overall Survival in the OlympiA Trial of Adjuvant Olaparib
Posted: 03/30/2022 | By: Sarah Campen, PharmD

Question 1 of 5

After a median follow-up of 3.5 years:

Choose 1

A
Adjuvant olaparib did not significantly improve invasive disease–free survival in patients compared with placebo
B
Fewer deaths were reported in the olaparib group vs the placebo group, with a 32% reduction in the risk of death compared with placebo
C
Adjuvant olaparib was discontinued in 22.3% of patients due to adverse events
D
The rate of overall survival with olaparib was 89.8% compared to 81.9% with placebo

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage